IQVIA Q3 Revenue Jumps 5.2% to $4.1B, Net Income Up 16.1%

TL;DR

**IQV's Q3 revenue and net income surged, but watch the year-to-date EPS dip and rising debt – it's a mixed bag, but the massive backlog is a bullish signal.**

AI Summary

IQVIA Holdings Inc. reported robust revenue growth for the three and nine months ended September 30, 2025. Revenues increased by 5.2% to $4.10 billion for the three-month period, up from $3.896 billion in 2024, and by 4.4% to $11.946 billion for the nine-month period, compared to $11.447 billion in 2024. Net income attributable to IQVIA Holdings Inc. rose significantly by 16.1% to $331 million for the three months ended September 30, 2025, from $285 million in the prior year, though it decreased by 9.6% to $846 million for the nine-month period from $936 million in 2024. Diluted EPS increased to $1.93 from $1.55 for the quarter but fell to $4.86 from $5.08 year-to-date. The company's Research & Development Solutions segment was a primary growth driver, contributing $2.260 billion in revenue for the quarter. A key strategic highlight is the substantial remaining performance obligations of approximately $34.4 billion, with 85% expected to be recognized over the next five years, primarily from clinical research service contracts. The company also increased its current portion of long-term debt to $2.164 billion from $1.145 billion at December 31, 2024, and repurchased $1.032 billion of common stock during the nine-month period.

Why It Matters

IQVIA's strong revenue growth, particularly in Research & Development Solutions, signals continued demand for clinical research and healthcare intelligence, benefiting investors through increased earnings potential. The substantial $34.4 billion in remaining performance obligations provides long-term revenue visibility, offering stability for employees and a strong competitive position against rivals like LabCorp and Syneos Health. However, the increase in current long-term debt and the year-to-date decline in net income and EPS warrant investor scrutiny, as these could impact future profitability and shareholder returns. The company's ability to convert its significant backlog into recognized revenue will be crucial for sustained market leadership.

Risk Assessment

Risk Level: medium — While IQVIA shows strong revenue growth, the nine-month net income attributable to IQVIA Holdings Inc. decreased by 9.6% to $846 million from $936 million in 2024, and diluted EPS fell to $4.86 from $5.08. Additionally, the current portion of long-term debt significantly increased to $2.164 billion as of September 30, 2025, from $1.145 billion at December 31, 2024, indicating increased short-term financial obligations.

Analyst Insight

Investors should closely monitor IQVIA's debt management strategies and the conversion rate of its $34.4 billion remaining performance obligations into recognized revenue. Given the mixed financial performance with strong quarterly growth but a year-to-date decline in net income and EPS, a 'hold' position might be prudent, awaiting further clarity on how the company plans to leverage its backlog and manage its increased short-term debt.

Financial Highlights

revenue

$4.10B

net Income

$331M

eps

$1.93

cash Position

$1.814B

revenue Growth

+5.2%

Revenue Breakdown

Key Numbers

• $4.10B — Q3 2025 Revenues (Increased 5.2% from $3.896B in Q3 2024)
• $11.95B — YTD 2025 Revenues (Increased 4.4% from $11.447B in YTD 2024)
• $331M — Q3 2025 Net Income (Increased 16.1% from $285M in Q3 2024)
• $846M — YTD 2025 Net Income (Decreased 9.6% from $936M in YTD 2024)
• $1.93 — Q3 2025 Diluted EPS (Increased from $1.55 in Q3 2024)
• $4.86 — YTD 2025 Diluted EPS (Decreased from $5.08 in YTD 2024)
• $34.4B — Remaining Performance Obligations (85% expected to be recognized over the next five years)
• $2.164B — Current Portion of Long-Term Debt (Increased from $1.145B at December 31, 2024)
• $1.032B — Common Stock Repurchases (For the nine months ended September 30, 2025)
• 170.3M — Shares Outstanding (As of October 20, 2025)

Key Players & Entities

• IQVIA Holdings Inc. (company) — registrant
• $4.10 billion (dollar_amount) — revenues for three months ended September 30, 2025
• $3.896 billion (dollar_amount) — revenues for three months ended September 30, 2024
• $11.946 billion (dollar_amount) — revenues for nine months ended September 30, 2025
• $11.447 billion (dollar_amount) — revenues for nine months ended September 30, 2024
• $331 million (dollar_amount) — net income attributable to IQVIA Holdings Inc. for three months ended September 30, 2025
• $285 million (dollar_amount) — net income attributable to IQVIA Holdings Inc. for three months ended September 30, 2024
• $846 million (dollar_amount) — net income attributable to IQVIA Holdings Inc. for nine months ended September 30, 2025
• $936 million (dollar_amount) — net income attributable to IQVIA Holdings Inc. for nine months ended September 30, 2024
• $34.4 billion (dollar_amount) — remaining performance obligations as of September 30, 2025

FAQ

Risk Factors

• Data Privacy and Security Regulations [high — regulatory]: The company operates in a highly regulated environment, subject to stringent data privacy laws like GDPR and HIPAA. Non-compliance can lead to significant fines and reputational damage. The increasing complexity and global reach of these regulations pose an ongoing challenge.
• Competition and Market Saturation [medium — market]: The life sciences services market is competitive, with numerous players offering similar services. Intense competition could pressure pricing and market share. The company faces competition from both large, established firms and smaller, specialized providers.
• Integration of Acquisitions [medium — operational]: IQVIA has a history of strategic acquisitions. The successful integration of acquired businesses is critical for realizing synergies and achieving growth objectives. Failure to integrate effectively could disrupt operations and impact financial performance.
• Debt Management and Interest Rate Fluctuations [medium — financial]: The company has a significant amount of debt, with the current portion of long-term debt increasing to $2.164 billion. Rising interest rates could increase the cost of servicing this debt, impacting profitability. Effective management of its debt obligations is crucial.
• Contractual Disputes and Litigation [low — legal]: As a service provider, IQVIA is exposed to potential disputes with clients over contract terms and service delivery. Adverse outcomes in litigation could result in financial penalties and damage to client relationships.
• Changes in Healthcare Policies [medium — regulatory]: Evolving healthcare policies and reimbursement models in key markets can impact the demand for clinical research and other services. Unfavorable policy changes could reduce R&D spending by pharmaceutical and biotechnology companies.
• Talent Acquisition and Retention [medium — operational]: The company relies on a skilled workforce of scientists, researchers, and data analysts. Attracting and retaining top talent in a competitive labor market is essential for delivering high-quality services and driving innovation.
• Foreign Currency Exchange Rate Fluctuations [low — financial]: Operating globally exposes IQVIA to foreign currency exchange rate fluctuations, which can impact reported revenues and expenses. While the company engages in hedging activities, significant adverse movements can still affect financial results.

Industry Context

IQVIA operates in the highly competitive life sciences services sector, providing a broad range of solutions from clinical development to commercialization. The industry is characterized by increasing demand for data analytics, real-world evidence, and digital health solutions. Key trends include the growing complexity of clinical trials, the need for faster drug development, and the impact of regulatory changes globally.

Regulatory Implications

The company faces significant regulatory scrutiny related to data privacy (e.g., GDPR, HIPAA) and the conduct of clinical trials. Changes in healthcare policies and reimbursement landscapes in major markets can also impact demand for its services. Compliance with evolving regulations is critical to avoid penalties and maintain client trust.

What Investors Should Do

1. Monitor the trend in year-to-date net income and EPS.
2. Analyze the drivers behind the increase in the current portion of long-term debt.
3. Evaluate the utilization and impact of share repurchases.
4. Assess the sustainability of revenue growth from the R&D Solutions segment.
5. Scrutinize the management of operating expenses relative to revenue growth.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported revenues of $4.10 billion, up 5.2% year-over-year, and net income of $331 million, up 16.1%.
• 2025-09-30: End of Nine Months 2025 — Reported revenues of $11.946 billion, up 4.4% year-over-year, but net income decreased 9.6% to $846 million.
• 2024-12-31: End of Fiscal Year 2024 — The company had $1.145 billion in the current portion of long-term debt.
• 2025-09-30: As of September 30, 2025 — Remaining performance obligations stood at approximately $34.4 billion, with 85% expected within five years.
• 2025-09-30: Nine Months Ended September 30, 2025 — The company repurchased $1.032 billion of common stock.
• 2025-10-20: As of October 20, 2025 — Shares outstanding were reported at 170.3 million.

Glossary

Remaining Performance Obligations (RPO)

The total value of contracted services that have not yet been performed or recognized as revenue. It represents future revenue that is already under contract. (Indicates future revenue visibility and stability, with $34.4 billion expected to be recognized over the next five years.)

Diluted Earnings Per Share (EPS)

A measure of a company's profit allocated to each outstanding share of common stock, assuming all convertible securities and stock options were exercised. (Shows a decrease to $4.86 for the nine-month period, indicating a decline in profitability per share despite revenue growth.)

Cost of revenues, exclusive of depreciation and amortization

Direct costs associated with generating revenue, excluding non-cash expenses like depreciation and amortization. (This cost increased to $7.952 billion for the nine months, impacting the company's gross profit margins.)

Selling, general and administrative expenses (SG&A)

Costs incurred for marketing, sales, and general operational overhead not directly tied to the production of goods or services. (These expenses remained relatively stable at $1.531 billion for the nine months, suggesting controlled overhead.)

Depreciation and amortization

The systematic allocation of the cost of tangible assets (depreciation) and intangible assets (amortization) over their useful lives. (A non-cash expense that increased slightly to $827 million for the nine months.)

Restructuring costs

Expenses incurred due to significant reorganizations or restructuring of business operations. (These costs were $81 million for the nine months, indicating ongoing efforts to optimize operations.)

Noncontrolling interests

The portion of equity in a subsidiary that is not attributable to the parent company. (Minimal impact, with net income attributable to noncontrolling interests being negligible.)

Weighted average common shares outstanding

The average number of common shares outstanding during a period, used for EPS calculations. (The diluted weighted average shares decreased from 184.3 million in 2024 to 174.1 million in 2025 for the nine-month period, which can boost EPS if net income were stable.)

Year-Over-Year Comparison

Compared to the prior year, IQVIA Holdings Inc. demonstrated solid revenue growth, with Q3 revenues up 5.2% to $4.10 billion and year-to-date revenues up 4.4% to $11.946 billion. However, profitability metrics show a mixed picture: net income for Q3 surged 16.1% to $331 million, but year-to-date net income declined 9.6% to $846 million. Similarly, diluted EPS for Q3 improved to $1.93, but the year-to-date EPS fell to $4.86 from $5.08. A notable change is the significant increase in the current portion of long-term debt to $2.164 billion from $1.145 billion at the end of 2024, suggesting increased leverage or short-term financing needs.

Key Financial Figures

• $0.01 — ch Registered Common Stock, par value $0.01 per share IQV New York Stock Exchange

Filing Documents

• iqv-20250930.htm (10-Q) — 1502KB
• iqv-20250930xexhibit221.htm (EX-22.1) — 18KB
• iqv-20250930xexhibit311.htm (EX-31.1) — 9KB
• iqv-20250930xexhibit312.htm (EX-31.2) — 9KB
• iqv-20250930xexhibit321.htm (EX-32.1) — 6KB
• iqv-20250930xexhibit322.htm (EX-32.2) — 6KB
• iqv-20250930_g1.jpg (GRAPHIC) — 8KB
• 0001628280-25-046794.txt ( ) — 7987KB
• iqv-20250930.xsd (EX-101.SCH) — 55KB
• iqv-20250930_cal.xml (EX-101.CAL) — 80KB
• iqv-20250930_def.xml (EX-101.DEF) — 248KB
• iqv-20250930_lab.xml (EX-101.LAB) — 666KB
• iqv-20250930_pre.xml (EX-101.PRE) — 476KB
• iqv-20250930_htm.xml (XML) — 1194KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION 3 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2025 and 2024 4 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 7 Notes to Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37

—OTHER INFORMATION

PART II—OTHER INFORMATION 39 Item 1.

Legal Proceedings

Legal Proceedings 39 Item 1A .

Risk Factors

Risk Factors 39 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39

Other Information

Item 5. Other Information 40 Item 6. Exhibits 41

SIGNATURES

SIGNATURES 42 2 Table of contents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements IQVIA HOLDINGS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in millions, except per share data) 2025 2024 2025 2024 Revenues $ 4,100 $ 3,896 $ 11,946 $ 11,447 Cost of revenues, exclusive of depreciation and amortization 2,727 2,518 7,952 7,450 Selling, general and administrative expenses 514 522 1,531 1,539 Depreciation and amortization 286 278 827 811 Restructuring costs 20 28 81 71 Income from operations 553 550 1,555 1,576 Interest income ( 13 ) ( 13 ) ( 34 ) ( 36 ) Interest expense 189 170 536 499 Loss on extinguishment of debt — — 4 — Other (income) expense, net ( 31 ) 44 ( 5 ) ( 12 ) Income before income taxes and equity in earnings (losses) of unconsolidated affiliates 408 349 1,054 1,125 Income tax expense 76 65 193 189 Income before equity in earnings (losses) of unconsolidated affiliates 332 284 861 936 Equity in earnings (losses) of unconsolidated affiliates — 1 ( 14 ) — Net income 332 285 847 936 Net income attributable to noncontrolling interests ( 1 ) — ( 1 ) — Net income attributable to IQVIA Holdings Inc. $ 331 $ 285 $ 846 $ 936 Earnings per share attributable to common stockholders: Basic $ 1.94 $ 1.57 $ 4.90 $ 5.14 Diluted $ 1.93 $ 1.55 $ 4.86 $ 5.08 Weighted average common shares outstanding: Basic 170.2 182.1 172.6 182.1 Diluted 171.7 184.2 174.1 184.3 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of contents IQVIA HOLDINGS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2025 2024 2025 2024 Net income $ 332 $ 285 $ 847 $ 936 Comprehensive income adjustments: Unrealized (losses) gains on derivative instruments, net of income tax (benefit) expense of $( 2 ),$( 14 ),$( 8 ),$ 2 ( 5 ) ( 41 ) ( 26 ) 8

View Full Filing

View this 10-Q filing on SEC EDGAR